Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer-Reference-Cited by-同舟云学术

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Published:2018-04-23 Issue:5 Volume:24 Page:638-646
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Robichaux Jacqulyne P.,Elamin Yasir Y.,Tan Zhi,Carter Brett W.,Zhang Shuxing,Liu Shengwu,Li Shuai,Chen Ting,Poteete Alissa,Estrada-Bernal Adriana,Le Anh T.,Truini Anna,Nilsson Monique B.,Sun Huiying,Roarty Emily,Goldberg Sarah B.,Brahmer Julie R.,Altan Mehmet,Lu Charles,Papadimitrakopoulou Vassiliki,Politi Katerina,Doebele Robert C.,Wong Kwok-Kin,Heymach John V.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0007-9.pdf

Reference53 articles.

1. Bezjak, A. et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 24, 3831–3837 (2006).

2. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).

3. Wang, Y., Schmid-Bindert, G. & Zhou, C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther. Adv. Med. Oncol. 4, 19–29 (2012).

4. Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M. & Shepherd, F. A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26, 2350–2357 (2008).

5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735–742 (2011).

Cited by 332 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current management of uncommon EGFR mutations in non-small cell lung cancer;Current Problems in Cancer;2024-02

2. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan;JCO Precision Oncology;2024-01

3. Research Progress in Clinical Therapeutic Efficacy and Safety of HER2-Positive Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024

4. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

5. Histology and molecular testing;Lung Cancer;2024